echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top 10 pharmaceutical companies of global cancer in 2019

    Top 10 pharmaceutical companies of global cancer in 2019

    • Last Update: 2019-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tumor, with its complicated pathogenesis and increasing mortality year by year, has replaced cardiovascular disease and become the biggest market outlet In 2017, the tumor market broke the $100 billion mark for the first time, boasting the group medicine, while maintaining a 12.2% annual growth rate, which has become the focus of competition among pharmaceutical giants Tuyere will come, surrounded by heroes, tumor market surges, who will spend the flag of the top ten of the year? Based on the data disclosed in the 2018 annual report of pharmaceutical companies, this paper reviews the ranking and advantages of top 10 cancer companies If there is any omission, please leave a message below for correction 1、 Roche core: lung cancer, breast cancer, lymphoma tumor market known as the "running giant, iron Roche" said With the rise of tumor immune giants such as MSD and BMS, and the intervention of such giants as AstraZeneca, Aberdeen and Pfizer, the competition in the tumor market is becoming more and more fierce However, in the process of competing for the best, Roche still maintained its dominant position In addition to Roche, the only concern is the decline of three core monoclonal antibodies - rituximab, bevacizumab and trastuzumab after the expiration of their patents Breast cancer: in response to the expiration of the patent of trastuzumab, Roche launched a new HER2 + mAb drug, perjeta (patorzumab), which fully covers the whole clinical treatment of HER2 + breast cancer patients, significantly prolonging the medication cycle In 2018, the sales volume is close to 3 billion US dollars, maintaining a 27% rapid growth Lung cancer: Although the patents of bevacizumab and erlotinib have expired, with the expansion of clinical indications of PD-L1 mAb and erlotinib in NSCLC, the market of lung cancer has increased In December 18, FDA approved t-drug combined with bevacizumab and chemotherapy for the first-line treatment of NSCLC patients In March 2019, t-drug combined chemotherapy was approved by FDA for the first-line treatment of small cell lung cancer Compared with O and K, t-drug did not fall behind in the lung cancer market With the clinical advantages (34.8 vs 10.9 months) of clozatinib, alentinib has been approved as a first-line drug, with a rapid market growth Lymphoma: Roche acquired the upgraded version of gazyva with rituximab through acquisition The drug's 18-year sales volume was CHF 390 million, an increase of 40% In addition, the Bcl-2 inhibitor jointly developed with alberwin also achieved multiple lymphoma indications, but the drug data were not disclosed 2、 New base core: multiple myeloma (mm) new base, with its intensive work in mm market, has made great achievements, becoming the tumor giant next to Roche But the rise and fall of the company is in the hands of lenalidomide, a leading product, which accounts for 70% of the company's market share With no medicine, the influx of competitors and the expiration of patents in the next few years, Xinji has taken a step in cooperation with BMS Mm is an incurable disease The main goal of clinical treatment is to prolong the survival time of patients as much as possible Thanks to the expansion of the market and the increase of medication schedule (promoted to MM first-line medication), lenalidomide increased by 18% in 2018, with sales reaching US $9.685 billion, becoming the best-selling cancer drug In mm market, the biggest competitor of Xinji is Johnson & Johnson Its monoclonal antibody CD38 has been on the market since 15 years, and it has been among the first-line drugs in just three years, with a sales volume of 2 billion US dollars The MM battle has gradually spread to car-t therapy Car-t therapy bb2121, a new base for multiple myeloma, has been awarded a breakthrough drug by FDA The corresponding one is Johnson & Johnson's acquisition of car-t therapy lcar-b38m, a legendary car-t therapy in Nanjing 3、 Core of mosadong: non small cell lung cancer (NSCLC), cervical cancer mosadong, relying on the success of the best-selling PD-1 monoclonal antibody keytruda and cervical cancer vaccine, has become one of the first-line cancer giants However, the lack of product lines has also become the biggest bottleneck restricting the market growth of MSD Therefore, MSD has accelerated the process of M & a cooperation to enrich its product lines In 2017, it acquired half of the ownership of AstraZeneca PARP inhibitor with us $8.5 billion In 18 years, $5.8 billion was used to acquire half of the ownership of lumbrotini By 2016, when the first NSCLC (PD-L1 strong positive) was approved, keytruda began to counter attack the o medicine In 2017, he won the indication of high microsatellite instability (MSI-H) solid tumor, becoming the first drug based on biomarkers rather than tumor location, and the reputation of broad-spectrum anticancer drug spread rapidly; in October 2018, he won the last non scaly NSCLC first-line indication, declaring the full slam of NSCLC first-line drugs, including nearly 80% of NSCLC patients, and the lung cancer market has no one out of its kind Right In 2018, the revenue of K drug reached 7.171 billion US dollars, surpassing the o drug of BMS, becoming the best-selling PD-1 inhibitor, with a growth rate of 88% No surprise, within three years, K drug will replace lenalidomide and become the top cancer drug Gardasil 9, a nine price cervical cancer vaccine, has become a synonym for HPV vaccine China's listing has aroused the heartstrings of countless girls, but behind the high-speed growth carnival is a needle of loneliness 4、 BMS core: melanoma, NSCLC, CML, renal cancer, etc The development of BMS can be said to confirm the poem "all the time, all the world, all the heroes are not free" As the first company involved in tumor immunity, it launched the first CTLA-4 monoclonal antibody and the first PD-1 monoclonal antibody Its market performance soared, and in a few years, it was promoted to the first-line giant of tumor industry, which can be described as the boundless scenery However, the successive failures in the first-line indications of lung cancer (non-small cell lung cancer, small cell lung cancer) allowed mosadon and Roche to take advantage of the opportunity, and the market space was further compressed The failure of the market and the approval of the indications also made BMS heartless and opened the way to acquire the new base company It also means that JD and Tencent cooperate to challenge Ali in real life In recent two years, BMS company's o drug has been a bit unlucky in lung cancer indications, and has turned over in a number of large-scale phase III clinical trials In the failure of checkmate-026 in large-scale phase III clinical trial, drug o selected patients with PD-L1 (TPS > 5%) positive NSCLC, which lost the good opportunity of first-line NSCLC approval; in 2019, first-line NSCLC approval was repeatedly delayed due to data reasons In the indication of small cell lung cancer, checkmate-331, a large-scale phase III clinical trial of drug o, and checkmate-451, a phase III clinical trial of SCLC maintenance therapy (after first-line platinum chemotherapy), both failed, and there was no significant improvement in the overall survival period, progression free survival period and other important indicators The failure of drug o also indirectly contributed to the success of K and T in the lung cancer market It can be said that people and ghosts are on show, only BMS is being beaten In other indications - melanoma, renal cancer, liver cancer, gastric cancer With the advantages of early approval, drug o is slightly ahead of drug K and drug t In addition, in terms of early medication, the combination immunotherapy of drug O and epimab has been approved for the primary treatment of melanoma patients and primary treatment of renal cancer patients, providing assistance for these two mAbs Dasatinib, as an upgraded inhibitor of imatinib, can be used in chronic adult CML that is resistant or intolerant to other therapies including imatinib, and also has a good sales performance 5、 Johnson & Johnson core: lymphoma, multiple myeloma (mm), and prostate adenoma: Johnson & Johnson's tumor business revenue in 2018 was 9.25 billion US dollars, an increase of 21% compared with last year, which is undoubtedly due to the heavy bomb developed in recent two years These drugs have maintained a high-speed growth in their respective fields, with a long patent protection period, and Johnson & Johnson's tumor market will rise steadily in the next few years Mm is the most eye-catching in the market than daremoumab At the end of 2015, just three years later, relying on the breakthrough of clinical efficacy, the drug was transferred from the four line drug to the first line drug, and it wanted to have a high ratio with the new basic trial In 2018, the growth rate reached 63%, and the sales exceeded 2 billion US dollars J & J ibtini has won 2.6 billion US dollars in the overseas market of the United States, which is no less famous than its super heavyweight In August 2017, ibutini was listed in China In 2018, 80% of its price was cut to enter the medical insurance catalog The advantages of first mover and medical insurance will provide new impetus for ibutini's rapid growth In the prostate adenoma market, abitrone has maintained a growth rate of 39.6% in the face of the competition from Frayne, and is the best-selling prostate drug at present 6、 Amgen core: neutropenia, solid tumor bone metastasis Amgen, the old cancer force, now in the face of BMS, MSD and other rising stars appear a little dim The pain of core product patent expiration will become more and more obvious in the future However, in 2018, Amgen still won $8.52 billion in the tumor sector The growth of Amgen's most important product, Peugeot booth, has stagnated after the expiration of its patent, but the impact is not too big at present It has contributed $4.8 billion together with feugeot booth Desurmab, which is used for osteoporosis and solid tumor bone metastasis, has maintained a growth rate of 13% due to the lack of competition from heavyweight competitors in this field, and has become the heaviest bomb of amjin For panimib used in colorectal cancer, there will not be much space in the next few years due to the expiration of patents for (V) EGFR inhibitors such as bevacizumab, share saturation, and competition for immunomabs 7、 Novartis core: CML, melanoma, breast cancer, kidney cancer, Novartis is facing the same situation as Amgen Due to the impact of the expiration of imatinib patent, the high price car-t market performance is unsatisfactory, and the tumor market share continues to decline Compared with the slow decline after the expiration of peifeigeting's patent, imatinib of chemical medicine is a disaster after the expiration of the patent, and its market share has been less than the original one Even if I am not the blessing of the halo of drug God, I can't help sighing: I don't believe to look up and ask who can spare the patent! Due to the increased medical demand for myelofibrosis and polycythemia vera, the orphan drug lucotinib achieved a 26% increase In the breast cancer market, Everest and the second CDK4 / 6 inhibition work together, and Novartis is expected to make a breakthrough in the 10 billion scale breast cancer market The first car-t therapy, which is expected to win only $76 million, was dwarfed by Gilead's competition 8、 Pfizer core: breast cancer, renal cancer, NSCLC Pfizer, the first pharmaceutical factory in the universe, no longer in the era of blood lipid reduction, the vaccine and autoimmune market is weak, and began to focus on the tumor market In the breast cancer market, piperacillin, the CDK inhibitor, has become a first-line ER +, her2-breast cancer drug (accounting for 60%) by virtue of its effective curative effect Its sales performance has been climbing one after another, and it has become a Pfizer heavyweight product It is expected to become the best-selling breast cancer drug in the world in the next three years Pfizer spent $14 billion to acquire enzalutamide, a drug owned by medivation, as the best prostate cancer drug at this stage, with a growth rate of 18% in 18 years and a revenue of $699 million In NSCLC market, the first generation of ALK inhibitor, clozatinib, began to go downhill with the approval of the first-line medication of Roche alentinib Dakotinib, the second-generation EGFR inhibitor, was approved for marketing last year At the same time, dakotinib is the only EGFR inhibitor that can significantly improve the overall survival of patients, and it is expected to achieve good results 9、 AstraZeneca core: NSCLC, breast cancer, egg
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.